Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Judith Wolf, William Creech, Matthew Ellis

Premium

Vermillion said this week it has appointed Judith Wolf as chief medical officer.

Wolf currently serves as division chief of surgical oncology and vice chair of the department of oncology services at the Banner MD Anderson Cancer Center in Arizona.


ERBA Diagnostics said this week that it has appointed William Creech as vice president of sales and marketing.

Creech was previously vice president of sales and marketing at Vermillion.


Baylor College of Medicine has named Matthew Ellis as its director of the Lester and Sue Smith Breast Center, effective Sept. 1. He succeeds Kent Osborne, who is leaving his post to focus on his other job as director of Baylor's Dan L. Duncan Cancer Center.

Ellis, currently a professor of medicine at Washington University School of Medicine, is focused on studying the molecular underpinnings of breast cancer. BCM received a grant from the Cancer Prevention Research Institute of Texas to recruit Ellis, who will bring a large resource of patient-derived xenografts with him.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.